Grifols, S.A.
GRFSHealthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.
- Revenue
- +9.37%
- EPS
- +59.8%
- Free cash flow
- +4.11%
- Total debt
- −6.08%
Quarter to September 2026, against a year earlier
Follow GRFS
Alert me
Grifols, S.A. (GRFS) P/E ratio
As of 6 November 2026, Grifols, S.A. (GRFS) trades at a P/E ratio of 18.2×. Over the past ten years it has ranged from 8.8× (December 2021) to 59.2× (December 2023); the current reading is higher than 29% of that period. That is below the Drug Manufacturers General industry median of 26.5× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 20.2× | (4.44%) |
| FY2024 | 21.2× | (62.61%) |
| FY2023 | 56.6× | 123.53% |
| FY2022 | 25.3× | 23.56% |
| FY2022 | 20.5× | 3.65% |
| FY2021 | 19.8× | 9.03% |
| FY2021 | 18.1× | 2.77% |
| FY2020 | 17.6× | (14.36%) |
| FY2020 | 20.6× | 1.33% |
| FY2019 | 20.3× | 10.42% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 15.8× | (8.85%) |
| Mar 2026 | 17.3× | (14.22%) |
| Dec 2025 | 20.2× | (18.47%) |
| Sep 2025 | 24.8× | 10.18% |
| 29 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| AMRN Amarin Corporation PLC compare | n/m |
| NVO Novo Nordisk A/S compare | 10.1× |
| BMY Bristol Myers Squibb Company compare | 13.7× |
| GSK GSK PLC Sponsored ADR compare | 16.7× |
| OGN Organon & Co. compare | 17.3× |
| GRFS Grifols, S.A. | 18.2× |
| SNY Sanofi compare | 23.3× |
| BIIB Biogen Inc. compare | 105× |
| NSRX Nasus Pharma Ltd. compare | — |
| Drug Manufacturers General industry median | 26.5× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on GRFS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement